small nuclear ribonucleoprotein polypeptide G pseudogene 19Genealiases: []
Q-omics provides the consensus-scored SNRPGP19 profile across patient tissues and cancer cell-line models. SNRPGP19 expression is associated with patient survival in 7 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SNRPGP19 is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, SNRPGP19 RNA expression shows 5,977 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, LUSC, and STAD as cancer lineages where SNRPGP19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPGP19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPGP19 survival associations across molecular data types. SNRPGP19 RNA expression shows survival associations in the most cancer types (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPGP19 RNA expression–survival associations across cancer types. High SNRPGP19 expression shows unfavorable associations in KICH, LUSC, STAD, BRCA, ACC and THCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SNRPGP19 RNA expression.
This table summarizes SNRPGP19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNRPGP19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPGP19 shows lower tumor expression in LUSC and THCA. The LUSC box plot shows higher SNRPGP19 RNA expression in normal versus tumor tissue (log2 FC = −0.050, t-test p = .011).
This table shows molecular features associated with SNRPGP19 in patient tissues and cancer cell lines. In patient samples, SNRPGP19 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
